METIMMOX-3: Biomarker-Selected Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating With Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer
Sponsor: Akershus University Hospital
Phase: 2
Disease: Metastatic colorectal cancer, Microsatellite-stable colorectal cancer, Mismatch-repair-proficient colorectal cancer
EU trial number: 2026-526317-29-00
Population: Patients with previously untreated unresectable abdominal metastases from microsatellite-stable, mismatch-repair-proficient colorectal carcinoma, initially receiving oxaliplatin-based chemotherapy and bevacizumab; only those with intermediate tumor mutational burden (≥9 mutations/Mb) or BRAF V600E mutation continue to alternating tislelizumab treatment.
Register Investigator Interest
Interested in offering this trial to suitable patients?